CellShells Bioscience (Suzhou) Co Ltd in the China (Jiangsu) Pilot Free Trade Zone Suzhou Area (Suzhou FTZ) in SIP recently finished the registration of its data assets as intellectual property for stock option trusteeship. This is the first case of integrating data-based intellectual property with stock options in China. It has opened up a brand-new path for conversion of data asset value for tech companies, further activating the potential of the data element market.

Founded in 2024, CellShells Bioscience specializes in organ-on-a-chip technology, providing efficient and innovative solutions for activities such as drug development and disease model building. In the field of neuroscience, where it has long established its expertise, the company has developed the “Neural Network Connectivity Quantitative Dataset Based on Organ-on-a-Chip and AI Image Recognition”. This dataset provides stable and standardized data support for both neuro-pharmaceutical screening and research.

       Leveraging the Jiangsu Equity Exchange’s comprehensive stock rights platform, the company has pioneered an innovative practice of using legally registered data-based intellectual property as its core asset to establish stock option agreements with its key team, thereby aligning this team with the long-term value of the data asset and injecting robust momentum for sustained advancement in technology innovation.

February 6, 2026